Shares of Neon Therapeutics Inc (NASDAQ:NTGN) have received a consensus recommendation of “Buy” from the nine analysts that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $16.57.
Several brokerages have recently commented on NTGN. Morgan Stanley decreased their price objective on shares of Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating on the stock in a report on Tuesday, July 16th. Zacks Investment Research lowered shares of Neon Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. Mizuho set a $21.00 price objective on shares of Neon Therapeutics and gave the stock a “buy” rating in a report on Monday, July 1st. Robert W. Baird assumed coverage on shares of Neon Therapeutics in a report on Thursday, July 25th. They set an “outperform” rating and a $15.00 target price on the stock. Finally, HC Wainwright increased their target price on shares of Neon Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th.
A number of institutional investors have recently added to or reduced their stakes in NTGN. Marshall Wace North America L.P. purchased a new stake in shares of Neon Therapeutics in the 1st quarter valued at approximately $49,000. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Neon Therapeutics by 100.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,000 shares of the company’s stock valued at $65,000 after purchasing an additional 5,000 shares during the last quarter. Rhumbline Advisers purchased a new stake in shares of Neon Therapeutics in the 1st quarter valued at approximately $78,000. Bank of New York Mellon Corp increased its position in shares of Neon Therapeutics by 17.6% in the 4th quarter. Bank of New York Mellon Corp now owns 19,427 shares of the company’s stock valued at $98,000 after purchasing an additional 2,905 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Neon Therapeutics by 42.7% in the 4th quarter. Bank of America Corp DE now owns 21,712 shares of the company’s stock valued at $109,000 after purchasing an additional 6,493 shares during the last quarter. Institutional investors own 69.53% of the company’s stock.
Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.03). Equities research analysts expect that Neon Therapeutics will post -2.61 earnings per share for the current year.
About Neon Therapeutics
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Featured Article: CBOE Russell 2000® Volatility Index
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.